GlassScriptPhysician profile
Robert Stagliano
NPI 1134158108
$5,665.42
in general payments reported to CMS, 2019-2025
44 companies · $765 in 2025
The $765 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,009 · 2020: $475 · 2021: $805 · 2022: $701 · 2023: $502 · 2024: $407 · 2025: $765.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,675.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,675.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $688.97 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $558.16 | 2021-2025 | Ubrelvy |
| Novo Nordisk INC | $422.54 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amarin Pharma, INC. | $356.42 | 2019 | |
| Pfizer INC. | $351.75 | 2019-2025 | |
| Glaxosmithkline, LLC. | $305.06 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $290.31 | 2019-2023 | Stiolto Respimat, Spiriva Respimat |
| Abbott Laboratories | $284.48 | 2022-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $224.82 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Esperion Therapeutics, INC. | $224.25 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $194.30 | 2019-2025 | Zoryve |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $153.04 | 2019-2025 | Xifaxan |
| Allergan, INC. | $144.47 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $141.19 | 2019-2023 | Camzyos, Eliquis |
| Sanofi-Aventis U.S. LLC | $137.43 | 2019 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Stagliano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.